Literature DB >> 9294410

In vivo microdialysis studies on somatodendritic dopamine release in the rat substantia nigra: effects of unilateral 6-OHDA lesions and GDNF.

A F Hoffman1, C G van Horne, S Eken, B J Hoffer, G A Gerhardt.   

Abstract

Dopamine (DA) release and metabolism within the substantia nigra (SN) were studied in normal rats, rats with unilateral 6-hydroxydopamine (6-OHDA) lesions, and 6-OHDA-lesioned rats treated with glial cells line-derived neurotrophic factor (GDNF). Animals with > 99% DA depletions, as determined by apomorphine-induced circling behavior, also showed significant deficits in several measures of spontaneous motor activity. In vivo microdialysis recordings in the SN were carried out in normal and unilaterally 6-OHDA-lesioned rats. Basal levels of DNA were detectable only in the dialysates of normal animals, and basal levels of t he primary DA metabolites 3,4-dihydroxyphenylacetic acid and homovanillic acid were found to be significantly reduced in the SN of 6-OHDA-lesioned animals. In the presence of d-amphetamine, either alone or in combination with potassium, significant reductions in DA release were observed in the SN of 6-OHDA-lesioned animals compared to normal animals. Potassium-evoked DA release alone was not significantly different between the groups. A single intranigral administration of GDNF into 6-OHDA-lesioned animals elicited a significant reduction in apomorphine-induced rotation behavior and a significant increase in spontaneous motor activities. These behavioral changes were apparent at 1 week and persisted through 4 weeks following treatment. In vivo microdialysis showed that, although DA metabolism was altered 1 week following GDNF treatment, DA release was not significantly affected until 4 weeks following treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9294410     DOI: 10.1006/exnr.1997.6571

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  7 in total

1.  Neurturin protects against 6-hydroxydopamine-induced reductions in evoked dopamine overflow in rat striatum.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Int       Date:  2010-07-06       Impact factor: 3.921

2.  Neurturin effects on nigrostriatal dopamine release and content: comparison with GDNF.

Authors:  Wayne A Cass; Laura E Peters
Journal:  Neurochem Res       Date:  2010-01-30       Impact factor: 3.996

3.  Effects of intrastriatal GDNF on the response of dopamine neurons to 6-hydroxydopamine: time course of protection and neurorestoration.

Authors:  Ann D Cohen; Michael J Zigmond; Amanda D Smith
Journal:  Brain Res       Date:  2010-11-06       Impact factor: 3.252

4.  Dopamine neuron stimulating actions of a GDNF propeptide.

Authors:  Luke H Bradley; Josh Fuqua; April Richardson; Jadwiga Turchan-Cholewo; Yi Ai; Kristen A Kelps; John D Glass; Xiuquan He; Zhiming Zhang; Richard Grondin; O Meagan Littrell; Peter Huettl; Francois Pomerleau; Don M Gash; Greg A Gerhardt
Journal:  PLoS One       Date:  2010-03-18       Impact factor: 3.240

5.  Presynaptic involvement in the nicotine prevention of the dopamine loss provoked by 6-OHDA administration in the substantia nigra.

Authors:  J Andrés Abin-Carriquiry; Ronald McGregor-Armas; Gustavo Costa; Jessika Urbanavicius; Federico Dajas
Journal:  Neurotox Res       Date:  2002-03       Impact factor: 3.911

6.  Electrochemical Selectivity Achieved Using a Double Voltammetric Waveform and Partial Least Squares Regression: Differentiating Endogenous Hydrogen Peroxide Fluctuations from Shifts in pH.

Authors:  Carl J Meunier; Edwin C Mitchell; James G Roberts; Jonathan V Toups; Gregory S McCarty; Leslie A Sombers
Journal:  Anal Chem       Date:  2018-01-05       Impact factor: 6.986

7.  RET signaling does not modulate MPTP toxicity but is required for regeneration of dopaminergic axon terminals.

Authors:  Sebastian Kowsky; Charlotte Pöppelmeyer; Edgar R Kramer; Björn H Falkenburger; Anja Kruse; Rüdiger Klein; Jörg B Schulz
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-04       Impact factor: 11.205

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.